BACKGROUND: Pancreatic adenocarcinoma (PAC) is part of several cancer predisposition syndromes; however, indications for genetic counseling/testing are not well-defined. In the current study, the authors sought to determine mutation prevalence and characteristics that are predictive of an inherited predisposition for PAC. METHODS: A total of 175 consecutive patients with PAC who underwent clinical genetics assessment at Memorial Sloan Kettering Cancer Center between 2011 and 2014 were identified. Clinical data, family history, and germline results were evaluated. RESULTS: Among 159 patients with PAC who pursued genetic testing, 24 pathogenic mutations were identified (15.1%; 95% confidence interval, 9.5%-20.7%), including BRCA2 (13 mutations), BRCA1 (4 mutations), p16 (2 mutations), PALB2 (1 mutation), and Lynch syndrome (4 mutations). BRCA1/BRCA2 prevalence was 13.7% in Ashkenazi Jewish (AJ) patients (95 patients) and 7.1% in non-AJ patients (56 patients). In AJ patients with a strong, weak, or absent family history of BRCA-associated cancers, the mutation prevalence was 16.7%, 15.8%, and 7.4%, respectively. The mean age at the time of diagnosis in all mutation carriers was 58.5 years (range, 45-75 years) compared with 64 years (range, 27-87 years) in those not carrying a mutation (P = .02). Although BRCA2 was the most common mutation identified, no patients with early-onset PAC (diagnosed at age ≤ 50 years) harbored a BRCA2 mutation and the mean age at diagnosis in BRCA2 carriers was equivalent to that of individuals who were not mutation carriers (P = .34). Mutation prevalence in patients with early-onset disease (21 patients) was 28.6%, including BRCA1 (2 mutations), p16 (2 mutations), MSH2 (1 mutation), and MLH1 (1 mutation). CONCLUSIONS: Mutations in BRCA2 account for > 50% of patients with PAC with an identified susceptibility syndrome. AJ patients were found to have high BRCA1/BRCA2 prevalence regardless of personal/family history, suggesting that ancestry alone indicates a need for genetic evaluation. With the exception of BRCA2-associated PAC, an inherited predisposition for PAC is associated with an earlier age at PAC diagnosis, suggesting that this subset of patients may also represent a population warranting further evaluation.
BACKGROUND:Pancreatic adenocarcinoma (PAC) is part of several cancer predisposition syndromes; however, indications for genetic counseling/testing are not well-defined. In the current study, the authors sought to determine mutation prevalence and characteristics that are predictive of an inherited predisposition for PAC. METHODS: A total of 175 consecutive patients with PAC who underwent clinical genetics assessment at Memorial Sloan Kettering Cancer Center between 2011 and 2014 were identified. Clinical data, family history, and germline results were evaluated. RESULTS: Among 159 patients with PAC who pursued genetic testing, 24 pathogenic mutations were identified (15.1%; 95% confidence interval, 9.5%-20.7%), including BRCA2 (13 mutations), BRCA1 (4 mutations), p16 (2 mutations), PALB2 (1 mutation), and Lynch syndrome (4 mutations). BRCA1/BRCA2 prevalence was 13.7% in Ashkenazi Jewish (AJ) patients (95 patients) and 7.1% in non-AJ patients (56 patients). In AJ patients with a strong, weak, or absent family history of BRCA-associated cancers, the mutation prevalence was 16.7%, 15.8%, and 7.4%, respectively. The mean age at the time of diagnosis in all mutation carriers was 58.5 years (range, 45-75 years) compared with 64 years (range, 27-87 years) in those not carrying a mutation (P = .02). Although BRCA2 was the most common mutation identified, no patients with early-onset PAC (diagnosed at age ≤ 50 years) harbored a BRCA2 mutation and the mean age at diagnosis in BRCA2 carriers was equivalent to that of individuals who were not mutation carriers (P = .34). Mutation prevalence in patients with early-onset disease (21 patients) was 28.6%, including BRCA1 (2 mutations), p16 (2 mutations), MSH2 (1 mutation), and MLH1 (1 mutation). CONCLUSIONS: Mutations in BRCA2 account for > 50% of patients with PAC with an identified susceptibility syndrome. AJ patients were found to have high BRCA1/BRCA2 prevalence regardless of personal/family history, suggesting that ancestry alone indicates a need for genetic evaluation. With the exception of BRCA2-associated PAC, an inherited predisposition for PAC is associated with an earlier age at PAC diagnosis, suggesting that this subset of patients may also represent a population warranting further evaluation.
Authors: Kasmintan A Schrader; Kelly L Stratton; Rajmohan Murali; Yael Laitman; Luca Cavallone; Lily Offit; Yong Hannah Wen; Tinu Thomas; Sohela Shah; Rohini Rau-Murthy; Christopher Manschreck; Erin Salo-Mullen; Ebun Otegbeye; Marina Corines; Liying Zhang; Larry Norton; Clifford Hudis; Robert J Klein; Noah D Kauff; Mark Robson; Zsofia K Stadler; Daniel A Haber; Steven M Lipkin; Eitan Friedman; William D Foulkes; David Altshuler; Joseph Vijai; Kenneth Offit Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: C J van Asperen; R M Brohet; E J Meijers-Heijboer; N Hoogerbrugge; S Verhoef; H F A Vasen; M G E M Ausems; F H Menko; E B Gomez Garcia; J G M Klijn; F B L Hogervorst; J C van Houwelingen; L J van't Veer; M A Rookus; F E van Leeuwen Journal: J Med Genet Date: 2005-09 Impact factor: 6.318
Authors: G H Su; R H Hruban; R K Bansal; G S Bova; D J Tang; M C Shekher; A M Westerman; M M Entius; M Goggins; C J Yeo; S E Kern Journal: Am J Pathol Date: 1999-06 Impact factor: 4.307
Authors: Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber Journal: J Natl Cancer Inst Date: 2002-09-18 Impact factor: 13.506
Authors: Fay Kastrinos; Bhramar Mukherjee; Nabihah Tayob; Fei Wang; Jennifer Sparr; Victoria M Raymond; Prathap Bandipalliam; Elena M Stoffel; Stephen B Gruber; Sapna Syngal Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Cristina R Ferrone; Douglas A Levine; Laura H Tang; Peter J Allen; William Jarnagin; Murray F Brennan; Kenneth Offit; Mark E Robson Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: J Iqbal; A Ragone; J Lubinski; H T Lynch; P Moller; P Ghadirian; W D Foulkes; S Armel; A Eisen; S L Neuhausen; L Senter; C F Singer; P Ainsworth; C Kim-Sing; N Tung; E Friedman; M Llacuachaqui; S Ping; S A Narod Journal: Br J Cancer Date: 2012-10-25 Impact factor: 7.640
Authors: Neil Vasan; Maria Ignez Braghiroli; Alexander N Shoushtari; Richard Kinh Gian Do; Marcia Edelweiss; Ali Shamseddine; Walid Faraj; Deborah Mukherji; Ali Haydar; Ashwaq Olayan; Fouad Sabatin; Rita Assi; Imane El Dika; Leonard B Saltz; Ghassan K Abou-Alfa; Eileen M O'Reilly Journal: J Gastrointest Oncol Date: 2017-06
Authors: Ritu R Singh; Johanna Goldberg; Anna M Varghese; Kenneth H Yu; Wungki Park; Eileen M O'Reilly Journal: Cancer Treat Rev Date: 2019-03-22 Impact factor: 12.111
Authors: Maeve A Lowery; David P Kelsen; Marinela Capanu; Sloane C Smith; Jonathan W Lee; Zsofia K Stadler; Malcolm J Moore; Hedy L Kindler; Talia Golan; Amiel Segal; Hannah Maynard; Ellen Hollywood; MaryEllen Moynahan; Erin E Salo-Mullen; Richard Kinh Gian Do; Alice P Chen; Kenneth H Yu; Laura H Tang; Eileen M O'Reilly Journal: Eur J Cancer Date: 2017-12-08 Impact factor: 9.162